Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Presentation of benefits and harms of antidepressants on websites: A cross-sectional study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies

    Research output: Contribution to journalReviewResearchpeer-review

  1. Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. General health checks in adults for reducing morbidity and mortality from disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Increased incidence of cervical cancer in Sweden: an unlikely link with human papillomavirus (HPV) vaccination

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations

BACKGROUND: Millions of people are treated with antidepressants like selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). This clinical practice is based on short-term trials that have exaggerated the benefits and underestimated the harms. We also know too little about long-term harms.

AIM: To assess harms of SSRIs and SNRIs that persist after end of drug intake.

METHODS: Systematic review of placebo-controlled randomised trials of any length in patients with a psychiatric diagnosis and a follow-up of at least six months. Our primary outcomes were mortality, functional outcomes, quality of life and core psychiatric events. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials and checked the references for eligible articles. One researcher extracted data and another checked the data extraction.

RESULTS: Our searches returned 9,153 unique records. We included 22 papers for 12 trials on SSRIs. Median intervention and follow-up periods were 15 and 52 weeks, respectively. Median number of randomised participants was 51; only two trials had a drop-out rate below 20%.Outcome reporting was less thorough during follow-up than for the intervention period and only two trials maintained the blind during follow-up. All authors concluded that the drugs were not beneficial in the long term.All trials reported harms outcomes selectively or did not report any. Only two trials reported on any of our primary outcomes (school attendance and number of heavy drinking days).

CONCLUSION: The randomised trials currently available cannot be used to investigate persistent harms of antidepressants.

Original languageEnglish
JournalInternational Journal of Risk and Safety in Medicine
Volume30
Issue number2
Pages (from-to)59-71
Number of pages13
ISSN0924-6479
DOIs
Publication statusPublished - 2019

ID: 58920333